Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 28.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | uctory Note, Item 2.01, Item 3.01, Item 3.03, Item 5.02 and Item 5.03 of this Current Report on Form 8-K is incorporated |
| 10.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors |
| 27.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appo |
| 30.11.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appo |
| 20.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 1.01 of Form 8-K, the information set forth under Item 5.02 of this Current Report on Form 8-K regarding the executive o |
| 30.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointme |
| 14.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | associated with, the April Reduction in Force. Item 5.02 Departure of Directors or Certain Officers; Election of Directo |
Stammdaten
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Unternehmen & Branche
| Name | Tourmaline Bio, Inc. |
|---|---|
| Ticker | TRML |
| CIK | 0001827506 |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 1,23 Mrd. USD |
| Beta | 1,58 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-06-30 | 10-Q | -23,092,000 | -0.90 | 269,295,000 | 259,192,000 | |
| 2025-03-31 | 10-Q | -22,970,000 | -0.89 | 287,498,000 | 279,863,000 | |
| 2024-12-31 | 10-K | -73,210,000 | -2.89 | 309,001,000 | 300,052,000 | |
| 2024-09-30 | 10-Q | -20,177,000 | -0.78 | 328,447,000 | 321,068,000 | |
| 2024-06-30 | 10-Q | -17,487,000 | -0.68 | 344,791,000 | 338,282,000 | |
| 2024-03-31 | 10-Q | -13,311,000 | -0.55 | 359,169,000 | 354,159,000 | |
| 2023-12-31 | 10-K | -42,124,000 | -8.87 | 210,295,000 | 205,042,000 | |
| 2023-09-30 | 10-Q | -5,591,000 | -5.16 | 151,061,000 | -47,407,000 | |
| 2023-06-30 | 10-Q | -16,129,000 | -16.29 | 159,121,000 | -42,529,000 | |
| 2023-03-31 | 10-Q | -7,502,000 | -8.28 | 172,607,000 | -26,841,000 | |
| 2022-12-31 | 10-Q | -73,900,000 | 193,715,000 | -19,732,000 | ||
| 2022-12-31 | 10-K | -19,701,000 | -22.46 | 9,098,000 | -19,732,000 | |
| 2022-09-30 | 10-Q | -19,011,000 | -4.59 | 206,544,000 | 194,867,000 | |
| 2022-06-30 | 10-Q | -18,096,000 | -0.44 | 220,916,000 | 210,742,000 | |
| 2022-03-31 | 10-Q | -18,259,000 | -0.45 | 237,246,000 | 226,030,000 | |
| 2021-12-31 | 10-Q | -47,800,000 | 251,422,000 | 242,809,000 | ||
| 2021-12-31 | 10-K | -47,833,000 | -1.64 | 251,422,000 | -226,000 | |
| 2021-09-30 | 10-Q | -12,941,000 | -0.32 | 261,325,000 | 255,649,000 | |
| 2021-06-30 | 10-Q | -11,352,000 | -0.41 | 272,814,000 | 267,353,000 | |
| 2021-03-31 | 10-Q | -9,299,000 | 144,900,000 | -46,466,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.